Angele Maki, PhD

Dr. Angèle Maki is a scientist turned dealmaker that has recently discovered a passion for leading a biotech startup that has huge potential to reshape the genetic medicines space. With nearly twenty years of deal-making experience spanning small biotech and big pharma, she is currently Senior Vice President and head of business development at ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.
Prior to ReCode, Angèle held business development roles with increasing responsibility starting at Medarex followed by BMS (which acquired Medarex), Genentech, 23andMe, Merck & Co, and Eli Lilly. During her career, she has successfully led diligence and negotiations on numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets. She was also a key player within the corporate venture arm of Lilly.
Angèle has a Ph.D. in biological chemistry from Stanford University where she carried out research into the mechanism of DNA bending using modified nucleotide bases. She completed postdoctoral work engineering zinc finger transcription factors at The Scripps Research Institute in La Jolla, and she has a B.Sc. in chemistry from the University of Winnipeg in Canada.